Φορτώνει......
P01.141 Different timing to use bevacizumab in patients with recurrent glioblastoma: early versus delayed administration
BACKGROUND: Glioblastoma (GBM) is the most baleful malignant brain tumor in adults. After a diagnosis of relapsed GBM, multimodality salvage treatment are not incisive enough to improve overall survival (OS) beyond a few months, and their best use and the timing is not well established. Bevacizumab...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Neuro Oncol |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Oxford University Press
2018
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6144527/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy139.183 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|